<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> contain populations of both cancerous and host immune cells whose malignant signaling interactions may define each patient's disease trajectory </plain></SENT>
<SENT sid="1" pm="."><plain>We used multiplexed phospho-flow cytometry to profile single cells within human follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and discovered a subpopulation of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells with impaired B cell antigen receptor (BCR) signaling </plain></SENT>
<SENT sid="2" pm="."><plain>The abundance of BCR-insensitive cells in each <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> negatively correlated with overall patient survival </plain></SENT>
<SENT sid="3" pm="."><plain>These <z:hpo ids='HP_0002665'>lymphoma</z:hpo> negative prognostic (LNP) cells increased as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> relapsed following chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>Loss of antigen receptor expression did not explain the absence of BCR signaling in LNP <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, and other signaling responses were intact in these cells </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, BCR signaling responses could be reactivated in LNP cells, indicating that BCR signaling is not missing but rather specifically suppressed </plain></SENT>
<SENT sid="6" pm="."><plain>LNP cells were also associated with changes to signaling interactions in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment </plain></SENT>
<SENT sid="7" pm="."><plain>Lower IL-7 signaling in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltrating T cells was observed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with high LNP cell counts </plain></SENT>
<SENT sid="8" pm="."><plain>The strength of signaling through T cell mediator of B cell function CD40 also stratified patient survival, particularly for those whose <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> contained few LNP cells </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, analysis of cell-cell interactions in <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> using signaling network profiles can identify and mechanistically define new populations of rare and clinically significant cells </plain></SENT>
<SENT sid="10" pm="."><plain>Both the existence of these LNP cells and their aberrant signaling profiles provide targets for new therapies for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>